233 related articles for article (PubMed ID: 29099660)
1. Ten-Year Retention Rate of Infliximab in Patients with Behçet's Disease-Related Uveitis.
Fabiani C; Sota J; Vitale A; Emmi G; Vannozzi L; Bacherini D; Lopalco G; Guerriero S; Venerito V; Orlando I; Franceschini R; Fusco F; Frediani B; Galeazzi M; Iannone F; Tosi GM; Cantarini L
Ocul Immunol Inflamm; 2019; 27(1):34-39. PubMed ID: 29099660
[TBL] [Abstract][Full Text] [Related]
2. Cumulative retention rate of adalimumab in patients with Behçet's disease-related uveitis: a four-year follow-up study.
Fabiani C; Sota J; Vitale A; Rigante D; Emmi G; Vannozzi L; Bacherini D; Lopalco G; Guerriero S; Gentileschi S; Capozzoli M; Franceschini R; Frediani B; Galeazzi M; Iannone F; Tosi GM; Cantarini L
Br J Ophthalmol; 2018 May; 102(5):637-641. PubMed ID: 28844047
[TBL] [Abstract][Full Text] [Related]
3. Comparative Study of Infliximab Versus Adalimumab in Refractory Uveitis due to Behçet's Disease: National Multicenter Study of 177 Cases.
Atienza-Mateo B; Martín-Varillas JL; Calvo-Río V; Demetrio-Pablo R; Beltrán E; Sánchez-Bursón J; Mesquida M; Adan A; Hernández MV; Hernández-Garfella M; Valls-Pascual E; Martínez-Costa L; Sellas-Fernández A; Cordero-Coma M; Díaz-Llopis M; Gallego R; García-Serrano JL; Ortego-Centeno N; Herreras JM; Fonollosa A; Garcia-Aparicio ÁM; Maíz-Alonso O; Blanco A; Torre-Salaberri I; Fernandez-Espartero C; Jovaní V; Peiteado D; Pato E; Cruz J; Férnandez-Cid C; Aurrecoechea E; García-Arias M; Castañeda S; Caracuel-Ruiz MA; Montilla-Morales CA; Atanes-Sandoval A; Francisco F; Insua S; González-Suárez S; Sanchez-Andrade A; Gamero F; Linares Ferrando LF; Romero-Bueno F; García-González AJ; González RA; Muro EM; Carrasco-Cubero C; Olive A; Prior Á; Vázquez J; Ruiz-Moreno O; Jiménez-Zorzo F; Manero J; Muñoz Fernandez S; Fernández-Carballido C; Rubio-Romero E; Pages FA; Toyos-Sáenz de Miera FJ; Martinez MG; Díaz-Valle D; López Longo FJ; Nolla JM; Álvarez ER; Martínez MR; González-López JJ; Rodríguez-Cundin P; Hernández JL; González-Gay MA; Blanco R
Arthritis Rheumatol; 2019 Dec; 71(12):2081-2089. PubMed ID: 31237427
[TBL] [Abstract][Full Text] [Related]
4. A 10-year follow-up of infliximab monotherapy for refractory uveitis in Behçet's syndrome.
Horiguchi N; Kamoi K; Horie S; Iwasaki Y; Kurozumi-Karube H; Takase H; Ohno-Matsui K
Sci Rep; 2020 Dec; 10(1):22227. PubMed ID: 33335139
[TBL] [Abstract][Full Text] [Related]
5. Long-term retention rates of adalimumab and infliximab in non-infectious intermediate, posterior, and panuveitis.
Fabiani C; Vitale A; Emmi G; Bitossi A; Lopalco G; Sota J; Guerriero S; Orlando I; Capozzoli M; Fusco F; Rana F; Iannone F; Frediani B; Galeazzi M; Vannozzi L; Tosi GM; Cantarini L
Clin Rheumatol; 2019 Jan; 38(1):63-70. PubMed ID: 29611087
[TBL] [Abstract][Full Text] [Related]
6. Long-term outcomes of infliximab in patients with Behçet's disease-associated uveitis.
Yamana S; Hasegawa E; Takeda A; Yawata N; Sonoda KH
Int Ophthalmol; 2023 Mar; 43(3):937-944. PubMed ID: 36057758
[TBL] [Abstract][Full Text] [Related]
7. Interleukin (IL)-1 inhibition with anakinra and canakinumab in Behçet's disease-related uveitis: a multicenter retrospective observational study.
Fabiani C; Vitale A; Emmi G; Lopalco G; Vannozzi L; Guerriero S; Gentileschi S; Bacherini D; Franceschini R; Frediani B; Galeazzi M; Iannone F; Tosi GM; Cantarini L
Clin Rheumatol; 2017 Jan; 36(1):191-197. PubMed ID: 27981463
[TBL] [Abstract][Full Text] [Related]
8. Predictors of sustained clinical response in patients with Behçet's disease-related uveitis treated with infliximab and adalimumab.
Fabiani C; Vitale A; Rigante D; Emmi G; Lopalco G; Sota J; Vannozzi L; di Scala G; Guerriero S; Orlando I; Franceschini R; Capozzoli M; Frediani B; Galeazzi M; Iannone F; Tosi GM; Cantarini L
Clin Rheumatol; 2018 Jun; 37(6):1715-1720. PubMed ID: 29671190
[TBL] [Abstract][Full Text] [Related]
9. Infliximab therapy in Behçet's uveitis.
Alizadegan F; Yalcinbayir O; Ucan Gunduz G; Pehlivan Y
J Fr Ophtalmol; 2022 Nov; 45(9):1036-1041. PubMed ID: 36150991
[TBL] [Abstract][Full Text] [Related]
10. Anti-TNF-α therapy in patients with refractory uveitis due to Behçet's disease: a 1-year follow-up study of 124 patients.
Calvo-Río V; Blanco R; Beltrán E; Sánchez-Bursón J; Mesquida M; Adán A; Hernandez MV; Hernandez Garfella M; Valls Pascual E; Martínez-Costa L; Sellas-Fernández A; Cordero Coma M; Díaz-Llopis M; Gallego R; Salom D; García Serrano JL; Ortego N; Herreras JM; Fonollosa A; García-Aparicio AM; Maíz O; Blanco A; Torre I; Fernández-Espartero C; Jovani V; Peiteado-Lopez D; Pato E; Cruz J; Fernández-Cid C; Aurrecoechea E; García M; Caracuel MA; Montilla C; Atanes A; Hernandez FF; Insua S; González-Suárez S; Sánchez-Andrade A; Gamero F; Linares L; Romero-Bueno F; García AJ; Almodovar R; Minguez E; Carrasco Cubero C; Olive A; Vázquez J; Ruiz Moreno O; Jiménez-Zorzo F; Manero J; Muñoz Fernández S; Rueda-Gotor J; González-Gay MA
Rheumatology (Oxford); 2014 Dec; 53(12):2223-31. PubMed ID: 24996907
[TBL] [Abstract][Full Text] [Related]
11. The effect of anti-tumor necrosis factor alpha agents on the outcome in pediatric uveitis of diverse etiologies.
Deitch I; Amer R; Tomkins-Netzer O; Habot-Wilner Z; Friling R; Neumann R; Kramer M
Graefes Arch Clin Exp Ophthalmol; 2018 Apr; 256(4):801-808. PubMed ID: 29455252
[TBL] [Abstract][Full Text] [Related]
12. Infliximab for uveitis of Behçet's syndrome: a trend for earlier initiation.
Guzelant G; Ucar D; Esatoglu SN; Hatemi G; Ozyazgan Y; Yurdakul S; Seyahi E; Yazici H; Hamuryudan V
Clin Exp Rheumatol; 2017; 35 Suppl 108(6):86-89. PubMed ID: 29148418
[TBL] [Abstract][Full Text] [Related]
13. Evaluation of the long-term efficacy and safety of infliximab treatment for uveitis in Behçet's disease: a multicenter study.
Takeuchi M; Kezuka T; Sugita S; Keino H; Namba K; Kaburaki T; Maruyama K; Nakai K; Hijioka K; Shibuya E; Komae K; Hori J; Ohguro N; Sonoda KH; Mizuki N; Okada AA; Ishibashi T; Goto H; Mochizuki M
Ophthalmology; 2014 Oct; 121(10):1877-84. PubMed ID: 24950593
[TBL] [Abstract][Full Text] [Related]
14. The effect of biologic therapy different from infliximab or adalimumab in patients with refractory uveitis due to Behçet's disease: results of a multicentre open-label study.
Santos-Gómez M; Calvo-Río V; Blanco R; Beltrán E; Mesquida M; Adán A; Cordero-Coma M; García-Aparicio ÁM; Valls Pascual E; Martínez-Costa L; Hernández MV; Hernandez Garfella M; González-Vela MC; Pina T; Palmou-Fontana N; Loricera J; Hernández JL; González-Gay MA
Clin Exp Rheumatol; 2016; 34(6 Suppl 102):S34-S40. PubMed ID: 27054359
[TBL] [Abstract][Full Text] [Related]
15. Comparison of the Treatment Results for Behçet Uveitis in Patients Treated with Infliximab and Interferon.
Yalçindag N; Köse HC
Ocul Immunol Inflamm; 2020; 28(2):305-314. PubMed ID: 31268743
[No Abstract] [Full Text] [Related]
16. Efficacy of Infliximab for Early Remission Induction in Refractory Uveoretinitis Associated with Behçet Disease: A 2-year Follow-up Study.
Keino H; Okada AA; Watanabe T; Nakayama M; Nakamura T
Ocul Immunol Inflamm; 2017 Feb; 25(1):46-51. PubMed ID: 27767359
[TBL] [Abstract][Full Text] [Related]
17. An open-label, prospective, single-arm study of switching from infliximab to cyclosporine for refractory uveitis in patients with Behçet's disease in long-term remission.
Ida Y; Takeuchi M; Ishihara M; Shibuya E; Yamane T; Hasumi Y; Kawano S; Kimura I; Mizuki N
Jpn J Ophthalmol; 2021 Nov; 65(6):843-848. PubMed ID: 34586526
[TBL] [Abstract][Full Text] [Related]
18. Comparative efficacy between adalimumab and infliximab in the treatment of non-infectious intermediate uveitis, posterior uveitis, and panuveitis: a retrospective observational study of 107 patients.
Fabiani C; Vitale A; Rigante D; Emmi G; Bitossi A; Lopalco G; Sota J; Guerriero S; Orlando I; Gentileschi S; Iannone F; Frediani B; Galeazzi M; Vannozzi L; Tosi GM; Cantarini L
Clin Rheumatol; 2019 Feb; 38(2):407-415. PubMed ID: 30099655
[TBL] [Abstract][Full Text] [Related]
19. Biologic Treatment Options for Retinal Neovascularization in Behçet's Disease.
Markomichelakis NN; Aissopou EK; Maselos S; Tugal-Tutkun I; Sfikakis PP
Ocul Immunol Inflamm; 2019; 27(1):51-57. PubMed ID: 28700280
[TBL] [Abstract][Full Text] [Related]
20. Successful Treatment with Infliximab for Refractory Uveitis in a Hemodialysis Patient with Behçet's Disease and a Review of the Literature for Infliximab Use in Patients on Hemodialysis.
Kurata I; Tsuboi H; Takahashi H; Abe S; Ebe H; Hagiwara S; Umeda N; Kondo Y; Ogishima H; Suzuki T; Matsumoto I; Hoshi S; Oshika T; Sumida T
Intern Med; 2015; 54(12):1553-7. PubMed ID: 26073249
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
